01—Abstract
Summary
Summary of the 8-K filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported third-quarter 2025 revenues, net of $120.7 milliona, consisting of $108.1 million in U.S. Attruby net product revenue, $4.3 million in royalty revenue, and $8.3 million in license and services revenue.
Total revenues, net were $120.7 millionb for the quarter compared with $2.7 million in the prior-year period. The company reported a net loss attributable to common stockholders of $182.7 million, or $0.95 per share, for the quarter, compared with $162.0 million, or $0.86 per share, a year earlier. Total operating costs and expenses rose to $265.9 million from $194.5 million, driven mainly by a $68.8 million increase in selling, general and administrative expenses tied to the Attruby launch.
Research and development expenses decreased, which the company attributed to the reprioritization of its R&D programs. As of October 25, 2025, 5,259 unique patient prescriptions had been written by 1,355 unique prescribers since Attruby's FDA approval in November 2024. Cash, cash equivalents and marketable securities totaled $645.9 millionc as of September 30, 2025, compared with $681.1 million as of December 31, 2024.
The filing attributes the decrease primarily to $389.5 milliond of net cash used in operating activities over the nine months, the $459.0 million repayment of the previous term loan, and $48.3 million of common stock repurchases. These outflows were partly offset by $563.0 million in net proceeds from the 2031 Notes and $297.0 million in net proceeds from the royalty interest purchase and sale agreement with HealthCare Royalty, a related party, and Blue Owl Capital. On the pipeline, the company reported positive topline results from the FORTIFY Phase 3 study of BBP-418 for LGMD2I/R9 and the CALIBRATE Phase 3 study of encaleret for ADH1.
It intends to file New Drug Applications for both programs with the FDA in the first half of 2026. The PROPEL 3 Phase 3 study of infigratinib in achondroplasia is expected to report topline results in early 2026.
02—Key points
Key Highlights
- Q3 2025 total revenues, net of $120.7 million, including $108.1 million of U.S. Attruby net product revenue, versus $2.7 million in Q3 2024
- Net loss attributable to common stockholders of $182.7 million, or $0.95 per share, for Q3 2025, compared with $162.0 million, or $0.86 per share, in Q3 2024
- Selling, general and administrative expenses rose to $137.6 million from $68.8 million, largely reflecting investments to support the Attruby commercial launch
- Cash, cash equivalents and marketable securities of $645.9 million at September 30, 2025, versus $681.1 million at December 31, 2024
- FORTIFY Phase 3 interim analysis of BBP-418 for LGMD2I/R9 met all primary and secondary endpoints, with an average 82% reduction in serum CK from baseline at 12 months; NDA planned for 1H 2026
- CALIBRATE Phase 3 study of encaleret in ADH1 met its primary endpoint, with 76% of participants achieving both serum and urine calcium within target ranges at Week 24 versus 4% on conventional therapy at Week 4; NDA planned for 1H 2026
- PROPEL 3 Phase 3 study of infigratinib in achondroplasia is fully enrolled with 114 participants randomized, with topline results expected in early 2026
03—Questions
Frequently Asked Questions
What drove BridgeBio's revenue in the third quarter of 2025?
Total revenues, net were $120.7 million, consisting of $108.1 million of U.S. Attruby net product revenue, $4.3 million of royalty revenue on BEYONTTRA net product sales in the EU and Japan, and $8.3 million of license and services revenue. The filing notes that year-to-date license and services revenue declined by $90.6 million, reflecting the timing of recognition of upfront payments from collaboration partners and regulatory-related milestones.
Why did operating expenses increase, and how did R&D spending change?
Total operating costs and expenses increased to $265.9 million from $194.5 million, primarily due to a $68.8 million rise in SG&A expenses supporting the Attruby launch and a $6.0 million increase in total cost of revenues from Attruby products sold. Research and development expenses decreased by $7.6 million to $112.9 million, which the company attributed to the reprioritization of its R&D programs.
How is Attruby's launch progressing?
As of October 25, 2025, 5,259 unique patient prescriptions had been written by 1,355 unique prescribers since FDA approval in November 2024. Management described the launch as accelerating, citing strong month-over-month growth in treatment-naïve patients. The filing also cites a JACC publication and HFSA data showing cumulative cardiovascular outcome effects within the first month of treatment.
What are the key near-term catalysts for BridgeBio's pipeline?
The company intends to file NDAs with the FDA for BBP-418 (LGMD2I/R9) and encaleret (ADH1) in the first half of 2026. Topline results from the PROPEL 3 Phase 3 study of infigratinib in achondroplasia are expected in early 2026. The company also plans to share Phase 3 portion data from the ACCEL 2/3 hypochondroplasia study in 2026, with Phase 2 data expected in the second half of 2026.
How did BridgeBio's cash position and financing change in 2025?
Cash, cash equivalents and marketable securities declined to $645.9 million from $681.1 million at year-end 2024. Net cash used in operating activities was $389.5 million for the nine months ended September 30, 2025. The company issued $575.0 million of 2031 Notes in February 2025 and received $300.0 million under the Royalty Purchase Agreement, while repaying $459.0 million of its previous term loan. The company stated that it is well capitalized to commercialize Attruby and advance its late-stage pipeline.
04—Continue